Non-invasive Prenatal Testing - A 360-degree View of the Market!

The close association between maternal age and the risk of developing chromosomal abnormalities in fetuses is common knowledge. Rising maternal age leads to an increased prevalence rate of babies born with a variety of diseases associated with chromosomal abnormalities. The Down Syndrome Education (DSE) association states that rate of occurrence of Down syndrome is about one in every 830 cases of child birth in the U.S. and about one in every 920 cases in Europe every year.

A variety of conventional prenatal genetic tests such as chorionic villus sampling (CVS) and amniocentesis involve invasive methods and carry the risk of facing a miscarriage. The rising population of women preferring pregnancy at later ages and technological advancements in the field of non-invasive prenatal tests allowing more accurate and extremely risk-free tests are driving an increased demand for non-invasive prenatal test (NIPT) technologies. Most new NIPTs analyze the cell-free DNA in the maternal plasma hence, they involve absolutely no risk of miscarriage resulting from the test.

Global NIPT Market at a Glance

According to the research report’s estimates, the global non-invasive prenatal testing market was worth US$0.5 bn in 2013 and is expected to grow at an incredible CAGR of 17.50% from 2014 to 2022 to reach a figure of US$2.4 bn by 2022. The impressive growth of the global non-invasive prenatal testing market is mainly due to the growing chances of fetuses developing chromosomal disorders such as Down syndrome, Turner syndrome, Edwards syndrome, Patau syndrome, and others. Non-invasive prenatal testing equipment is used for screening pregnant women who might have fetuses with these complications due to, among other reasons, higher maternal age than average.

Avail a Sample Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=374

The global non-invasive prenatal testing market is segmented on the basis of test and region. The tests in this market are Harmony, MaterniT21 PLUS, NIFTY, BambniTest, informaSeq, Panorama, VisibiliT, PrenaTest, verify, and others. Geographically, the global non-invasive prenatal testing market is segmented into Europe, Asia Pacific, North America, and Rest of the World.

All of these tests use the mother’s blood to study the cell-free fetal DNA. Back in 2011, MaterniT21 PLUS was the first ever non-invasive prenatal test launched in the market for diagnosing trisomy 21. Over the course of two years, this diagnostic test had already grabbed a share of 36.1% in the overall market. However, analysts predict that as the popularity of other testing equipment such as NIFTY, Panorama, and verify grows, MaterniT21 PLUS’ share will drop. Furthermore, demand for the Bambni test, which was recently approved by the CFDA, will also shoot upwards in the coming years.

Unfortunately, the global non-invasive prenatal testing market faces certain hurdles such as a tough regulatory framework and conservative ethical outlook towards prenatal testing. The other challenges complicating this situation are limitations of non-invasive prenatal tests and alternative screening and testing methods. However, the emerging economies of Asia Pacific are offering a new avenue for growth to the global non-invasive prenatal testing market in the near future.

Some of the important companies profiled in the global non-invasive prenatal testing market report are Laboratory Corporation of America Holdings, Natera Inc., Illumina Inc., Berry Genomics Co. Ltd., LifeCodexx AG, BGI Diagnostics, Sequenom Inc., and Ariosa Diagnostics Inc. The research report gives a complete understanding of the competitive landscape of the market and offers an insight into the financial overview, product portfolio, research and development activities, business and marketing strategies, and investment outlook in the coming years.